- Record: found
- Abstract: found
- Article: not found
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
David Cunningham
1 ,
Ian Chau ,
Deborah D Stocken ,
Juan W Valle ,
David Smith ,
William Steward ,
Peter G Harper ,
Janet Dunn ,
Catrin Tudur-Smith ,
Julia West ,
Stephen Falk ,
Adrian Crellin ,
Fawzi Adab ,
Joyce Thompson ,
Pauline Leonard ,
Joe Ostrowski ,
Martin Eatock ,
Werner Scheithauer ,
Richard Herrmann ,
John P Neoptolemos
Nov 20 2009
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP).